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Abstract: Invasive fungal infections (IFIs) are associated with high mortality rates and timely ap-
propriate antifungal therapy is essential for good outcomes. Emerging antifungal resistance among
Candida and Aspergillus spp., the major causes of IFI, is concerning and has led to the increasing
incorporation of in vitro antifungal susceptibility testing (AST) to guide clinical decisions. However,
the interpretation of AST results and their contribution to management of IFIs remains a matter of
debate. Specifically, the utility of AST is limited by the delay in obtaining results and the lack of
pharmacodynamic correlation between minimal inhibitory concentration (MIC) values and clinical
outcome, particularly for molds. Clinical breakpoints for Candida spp. have been substantially
revised over time and appear to be reliable for the detection of azole and echinocandin resistance
and for outcome prediction, especially for non-neutropenic patients with candidemia. However,
data are lacking for neutropenic patients with invasive candidiasis and some non-albicans Candida
spp. (notably emerging Candida auris). For Aspergillus spp., AST is not routinely performed, but may
be indicated according to the epidemiological context in the setting of emerging azole resistance
among A. fumigatus. For non-Aspergillus molds (e.g., Mucorales, Fusarium or Scedosporium spp.), AST
is not routinely recommended as interpretive criteria are lacking and many confounders, mainly host
factors, seem to play a predominant role in responses to antifungal therapy. This review provides an
overview of the pre-clinical and clinical pharmacodynamic data, which constitute the rationale for
the use and interpretation of AST testing of yeasts and molds in clinical practice.
Keywords: invasive aspergillosis; invasive candidiasis; mucormycosis; clinical breakpoints; minimal
inhibitory concentration; therapeutic response; pharmacodynamics
1. Introduction
Early appropriate antifungal therapy is a key determinant for the outcome of invasive
fungal infections (IFIs). While first and alternative therapeutic choices have been well de-
fined for the most frequent IFIs, such as invasive aspergillosis (IA) and invasive candidiasis
(IC) [1–5], or other less frequent IFIs (e.g., mucormycosis, fusariosis, scedosporiosis) [6,7],
much uncertainty remains about the role and interpretation of antifungal susceptibility
testing (AST). For some fungal pathogens, antifungal susceptibility patterns are well known
with limited intra-species variability (e.g., Scedosporium apiospermum). For others, the sig-
nificance of minimal inhibitory concentration (MIC) in predicting outcome is notoriously
weak and AST is not routinely recommended (e.g., Fusarium spp., Mucorales). However,
for Candida spp. and Aspergillus spp., the two most frequent fungal pathogens, emergence
of acquired antifungal resistance is a concern and definitions of clinical breakpoints (CBPs)
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are needed for the distinction between susceptible and resistant isolates in order to inform
appropriate antifungal selection. Both the Clinical and Laboratory Standards Institute
(CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
are working on establishing and updating CBPs for fungi. However, this task is complex,
as illustrated by the reassessment and changes of CBPs over time, some discrepancy in
CBP definitions between CLSI and EUCAST, and the absence of CBP definitions for some
fungus/antifungal drug combinations (Table 1).
Table 1. Comparison of CLSI and EUCAST clinical breakpoints of antifungal drugs for most relevant Candida and Aspergillus
spp. according to CLSI and EUCAST.
Species AMB FLC VRC POS CAS AND MCF











































C. glabrata ND 1 32 (SDD)(64)
0.002


















(0.5) ND ND ND ND ND ND
A. flavus ND ND (R) (R) ND ND ND ND ND ND ND ND ND ND
A. niger ND 1(4) (R) (R) ND ND ND ND ND ND ND ND ND ND
A. terreus (R) (R) (R) (R) ND ND ND 0.125(0.5) ND ND ND ND ND ND
Clinical breakpoints (CBPs) of the Clinical and Laboratory Standards Institute (CLSI, left column) and European Committee on Antimicrobial
Susceptibility Testing (EUCAST, right column). The numbers indicate the CBP [mg/L] for the distinction between susceptible “S” (≤the
indicated value) vs. non-susceptible. If an intermediate “I” or “susceptible dose-dependent” (SDD) category has been defined, the resistance
“R” cut-off (≥the indicated value) is mentioned in brackets. ND: no defined CBP (insufficient evidence), (R): the species is considered as
intrinsically resistant (susceptibility testing not recommended).
The aim of this article is to discuss the specific challenges of CBP definitions for
the most relevant fungal pathogens of IFIs and to review the current evidence of MIC/
outcome correlations.
2. The Challenges of Fungal Clinical Breakpoints (Cbps) Definitions
While often well established for antibacterials, CBPs for antifungals are associated with
greater uncertainty. This is in part due to the relatively low prevalence of IFI (in particular
mold infections) and some specific biological characteristics of fungal pathogens. In this
section, we will review these specific aspects (summarized in Figure 1).
2.1. Antifungal Susceptibility Testing (AST) of Fungi
Some nuances of AST exist. First, the artificial in vitro conditions of testing by mi-
crobroth dilution method may differ considerably from the actual pathophysiological
environment of IFIs. For example, invasive infections by molds affect mainly solid tissues
(rather than biological fluids), have relatively low fungal inoculum (compared to the very
high spore concentrations used in AST), and are often accompanied by tissue infarction
and necrosis that might preclude appropriate drug penetration at the site of infection.
In addition, the chemical composition of AST growth media differs from real pathogenic
conditions regarding important elements for fungal growth (e.g., glucose, iron, oxygen,
pH). Moreover, routine in vitro testing conditions do not take into account the possibility
of biofilm formation (especially for Candida spp.).
Different AST methods are used in routine across countries or local laboratories.
CLSI and EUCAST methods are recognized as the standard procedures and MICs derived
from these methods are used for definitions of epidemiological cut-off values (ECVs) and
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CBPs [8–11]. CLSI and EUCAST procedures exhibit some notable differences (e.g., related
to glucose content, spore inoculum, and reading interpretation), which may explain some
differences between their respective CBPs. Moreover, these methods are manual and fastid-
ious with an accepted margin of errors of up to ± two dilutions, which may considerably
impact MIC classification and interpretation. As a consequence, many laboratories use
commercially available microbroth dilution method (e.g., Sensititre YeastOneTM, Vitek-2TM)
or alternative methods (E-tests, agar disk diffusion), which may result in significant dif-
ferences in MIC results, despite relatively good essential agreements [12–15]. Important
interlaboratory discrepancies have also been notified regarding AST of caspofungin for
Candida spp., which resulted in the withdrawal of CBPs recommendations by EUCAST [16].
Another common issue with AST consists of the difficulties in MIC determination for some
drug/fungus, which may lead to discrepant results as a consequence of different subjective
interpretation from the reader. This is principally the case for antifungal drugs for which
there is a fungistatic activity and a trailing effect (e.g., Candida spp. and azoles, Aspergillus
spp. and echinocandins) or a paradoxical effect at increased concentrations (Candida spp.
and Aspergillus spp. with echinocandins). Moreover, the timing of reading (24 vs. 48 h),
which is not consistent across studies, may affect MIC determination.
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Finally and most importantly, AST results for fungi are usually obtained after a
significant delay due to their lower growth rate compared to bacteria (i.e., several days to
one week). Their interpretation for patient management is not made in “real time” and
their impact on outcome is therefore limited, since early and appropriate antifungal therapy
is of paramount importance for success.
2.2. Animal Pharmacodynamic/Pharamacokinetic (Pk/Pd) Models
In view of the paucity of clinical data, murine Pk/Pd models are important for as-
sessing the correlation between drug exposure/MIC and therapeutic response. These data
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are also taken into account for CBP definitions. However, an element of artificiality also
exists in these in vivo models as it compares to the complex clinical scenarios of IFIs in
humans. For example, much higher fungal inocula are administered to mice, an innately
non-susceptible species to fungal diseases, and only following intensive immunosup-
pressive regimens (e.g., myelotoxic drugs and corticosteroids) in order to induce a quick
and intense (rapidly fatal) infection. These conditions do not reflect the diversity of im-
munosuppressive and other co-morbid conditions in humans, the variety of IFI types and
localizations (e.g., pulmonary vs. cerebral aspergillosis, candidemia vs. non-candidemic
IC) and the actual timing and course of infection.
2.3. Pathophysiology of Invasive Fungal Infections (IFIs)
The distinct features of IFI (compared to bacterial infections) represent the most
important aspect of interpreting MIC results for fungi. Mold pathogens are relatively
infrequently isolated in culture and MICs are therefore lacking [17]. The diagnosis of IFI
(in particular for molds) is complex and associated with some degree of uncertainty with a
high rate of possible/probable infections and a lower rate of proven infections, which may
bias outcome analyses towards later diagnosis when the fungal burden is high. The timing
of diagnosis and initiation of antifungal therapy is also crucial and frequent delays in
IFI diagnosis have a considerable impact on outcome. The localization and extension of
infection may also affect the therapeutic response. For instance, drug penetration within
the different organs commonly affected by IFI (e.g., lungs, brain, or skin for IA, blood, or
peritoneal cavity for IC) may be quite different [18]. Most importantly, the outcome of IFI is
highly influenced by non-pharmacologic parameters, such as host variables (type, severity
and potential for recovery of underlying diseases and immunosuppression) or adjunct
therapies such as surgical interventions.
The assessment of therapeutic response in IFI is also difficult. While objective criteria
can be monitored in candidemia (e.g., clearance of blood cultures), the outcome evaluation
of invasive mold infections essentially relies on radiological interpretation, which may be
confounded by other infectious or non-infectious (e.g., sequela of surgery, inflammatory
reaction) radiological patterns with frequent initial worsening of lesions at the time of
neutrophil recovery. Moreover, the assessment of response for invasive mold infections
requires prolonged follow-up (weeks to months) and overall survival may be affected by
multiple intercurrent infections/events in these patients with severe underlying diseases,
such as cancer.
The rarity of some IFIs makes that many clinical pharmacodynamic studies present
very heterogeneous data pooling different type of IFI (IC, IA, and other IFIs) or different
species within a same genus (e.g., Candida albicans and non-albicans Candida spp.) or
different grading of IFI (proven/probable or possible, empiric treatment for suspected
IFI without documentation). Moreover, uniform therapeutic approaches are needed for
outcome analyses and IFIs often require multiple lines of different antifungal treatments
or drug combinations. Because of the delay in culture results, initial antifungal therapy is
usually empirical and then switched to targeted treatment.
3. Correlation between Mics and Outcome: Current Evidence
Determination of CBPs rely on ECVs derived from epidemiological studies, animal
Pk/Pd models and, most importantly, clinical studies supporting the reliability of MIC
in predicting outcomes. In this section, we will review the current evidence supporting a
correlation between antifungal drugs MIC and clinical outcomes for the most frequent IFIs
and for the three antifungal drug classes (polyenes, azoles, and echinocandins).
3.1. Invasive Candidiasis (IC)
IC is the most frequent IFI and consists of candidemia in a majority of cases, which
means that there is a relatively robust set of data with documented pathogen/MIC and
objectives parameters of outcome measurement, such as the clearance of candidemia. Based
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on these data, CBPs have been proposed by both CLSI and EUCAST for the most frequent
antifungal drug/pathogen combinations (Table 1). However, most trials of candidemia,
from which these data have been derived, have been performed in non-neutropenic patients.
Data from candidemia in neutropenic hematologic cancer patients or from non-candidemic
IC (e.g., hepato-splenic candidiasis, intra-abdominal candidiasis) are lacking [19].
3.2. Amphotericin B
Pk/Pd murine models of IC have shown that the Cmax/MIC ratio of amphotericin B
(AMB) was the determinant predictor of outcome with a ratio ≥10 resulting in maximal
fungicidal effect [20–22]. However, poor solubility of AMB at physiological pH and high
degrees of protein binding of insoluble drug may create a low ceiling (<100 ng/mL) for
concentration-dependent fungicidal activity in many tissues, resulting in accumulation of
non-bioactive protein bound [23].
AMB is currently not a first-line treatment of IC. Analyses of MIC/outcome correlation
are therefore scarce or relatively old. One study suggested a correlation for a MIC threshold
of 1 mg/L [24], while another study derived from a large randomized controlled trial of
AMB versus fluconazole did not found any correlation [25]. This lack of correlation was
confirmed by a more recent study among 107 candidemic episodes [26]. The narrow range
of MICs (0.25–1 mg/L) with a very limited number of cases with MIC ≥ 1 mg/L in these
later studies may explain these negative results.
3.3. Azoles
Fluconazole is the most widely used azole for the treatment of IC, being recommended
as first or second line treatment [1,2,5]. Other azoles are rarely used in this setting.
Murine models of C. albicans IC showed that a fluconazole AUC/MIC ratio >25–100
was the best parameter in predicting outcome [27,28]. For C. glabrata, murine models of IC
showed overall reduced efficacy of fluconazole independently from MIC results [29,30].
For fluconazole, the 24-h serum AUC is roughly equivalent to the daily dose in patients
with normal body habitus and renal function.
Mechanisms of azole resistance in Candida spp. are multiple and complex (e.g., muta-
tions in ERG11 target gene, overexpression of target genes and/or drug transporters) [31],
which can be associated with different levels of resistance, fitness, and virulence, and
renders MIC interpretation more complex.
Several clinical studies have tried to correlate the Candida MICs or other composite
pharmacodynamic parameters (dose/MIC, AUC/MIC) with outcome of IC (Table 2). Inter-
pretation of these studies is confounded by heterogeneity according to the susceptibility
testing method, the overall number of cases, and the rate of resistant isolates (i.e., their
statistical power) and the outcome definitions (e.g., overall or attributable mortality, differ-
ent composite scores of response to therapy), which could partly explain their discordant
results. Most importantly, the differences in the proportion of C. albicans versus non-albicans
Candida spp. (NAC) and the frequent pooled analysis of these cases represents the major
confounding factor. It is also important to mention that the CLSI method and interpretive
criteria have evolved over time, which precludes comparison between studies using the
old CLSI method/criteria (before 2012) and those using the new ones with MIC cut-offs
that are lower and closer to those from EUCAST [8–11,32].
The most recent and largest studies using the current methods (EUCAST, CLSI M38-
A2, or Sensititre YeastOneTM) tend to confirm a CBP around 2 mg/L for C. albicans [33–35].
However, this MIC/outcome relationship is absent or less obvious in studies reporting both
C. albicans and NAC cases [36,37]. Some studies limited to C. glabrata candidemia suggest
that the dose/AUC or AUC/MIC ratio could be more relevant to predict efficacy for this
pathogen exhibiting a wide range of fluconazole MIC and a dose-dependent response to
azole therapy [37,38].
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Table 2. Clinical studies correlating fluconazole minimal inhibitory concentrations (MIC) and outcome of invasive candidiasis (IC).
Study (First Author, Year,
Reference) N Cases Type of IC (Patients) Candida spp. AST Method Outcome Indicator Correlation MIC/Outcome
1 MIC Cut-Off
for Success
Rex (1995) 232 Candidemia(non-neutropenic)
C. albicans 56%
NAC 44% NCCLS (M27-P) Clinical response
2 No -
Lee (2000) [39] 32 All IC (mainlynon-neutropenic)
C. albicans 53%
NAC 47% NCCLS (M27-A) Clinical response
2 Trend MIC ≤ 8 mg/L
Kovacicova (2000) [40] 161 Candidemia(mixed) C. albicans and NAC (NS)
Disk diffusion
(some E-test) Attributable mortality Yes “susceptible”
Clancy (2005) [41] 32 Candidemia(mixed)
C. albicans 37%
NAC 63% NCCLS (M27-A) Clinical response
2 Yes MIC ≤ 8 mg/LDose/MIC > 50
Pai (2007) [42] 77 Candidemia(non-neutropenic)
C. albicans 64%





MIC ≤ 8 mg/L
Dosewn/MIC > 12
AUC/MIC > 55
Rodriguez-Tudela (2007) [34] 126 Candidemia (mainlynon-neutropenic)
C. albicans 58%
NAC 42% EUCAST Clinical response
2 Yes MIC ≤ 2 mg/LDose/MIC ≥ 33.5
Baddley (2008) [43] 84 Candidemia (mainlynon-neutropenic)
C. albicans 44%
NAC 56% CLSI (M27-A2)
Overall mortality
(week 6) Yes
MIC ≤ 32 mg/L
AUC/MIC ≥ 11.5
Dose/MIC ≥ 12.5
Eschenauer (2013) [38] 122 Candidemia (mainlynon-neutropenic) C. glabrata CLSI (M27-A3)
Clinical response
(day 14) Yes Dose/MIC > 12.5
Van Hal (2014) [35] 217 Candidemia (mainlynon-neutropenic) C. albicans SYO
Attributable mortality (day
30) Yes MIC ≤1 mg/L











Fernandez-Ruiz (2017) [36] 257 Candidemia (mainlynon-neutropenic)
C. albicans 54%
NAC 46% CLSI (M27-A3) EUCAST Clinical response
2 Trend MIC ≤ 0.25 mg/L (CLSI)













IC: invasive candidiasis, AST: antifungal susceptibility testing, MIC: minimal inhibitory concentration, NAC: non-albicans Candida spp., NCCLS: National Committee for Clinical Laboratory Standards, CLSI:
Clinical and Laboratory Standards Institute (former NCCLS), EUCAST: European Committee on Antimicrobial Susceptibility testing, SYO: Sensititre YeastOneTM, AUC = area under the time-concentration
curve, Dosewn = dose normalized to weight, NS: not specified. 1 Assessment of correlation MIC/outcome: Yes (p < 0.05)/Trend (p < 0.2)/No (p ≥ 0.2). 2 Clinical response was usually assessed with composite
parameters including clinical response, microbiological cure, overall mortality, relapsing candidemia.
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3.4. Echinocandins
The three echinocandins (caspofungin, anidulafungin, and micafungin) currently
represent the first choice treatment of IC [1,2,5].
The parameters best predicting efficacy of echinocandins in murine models of IC
were the Cmax/MIC and AUC/MIC ratios [44–46]. Caspofungin exhibits an important post-
antifungal effect with persistent therapeutic concentrations in tissues [46]. The AUC/MIC
targets were found to be similar for the three echinocandins when considering the free drug
concentration (because of the high rate of protein binding of these drugs), but notably higher
for C. albicans compared to C. glabrata or C. parapsilosis (ratios of 20 vs. 7, respectively) [47].
There is some controversy about the appropriateness of the currently recommended dosing
regimens, which could not be sufficient to achieve the targeted AUC/MIC ratios, in particular,
among critically-ill or neutropenic patients or in case of high body mass index [48–50].
For echinocandins, treatment failure has been clearly correlated to the presence of
FKS hotspot mutations conferring non-susceptibility across all echinocandins, which is
currently observed in about 5–10% of C. glabrata and 1–5% of C. albicans bloodstream
isolates in US [51–53]. Overall, the rates of echinocandin treatment failure for candidemia
due to FKS-mutant Candida spp. ranges from 60 to 90% [51,52,54,55], while the usual failure
rate of echinocandins in the big trials of candidemia is around 10 to 30% [56–59].
Clinical studies of MIC/outcome correlation for echinocandins are shown in Table 3.
Analyses derived from the caspofungin clinical trial database including several phase II
and III trials of IC and Candida esophagitis did not find any correlation between echinocan-
din MICs and outcome [60,61]. However, these studies have been performed before the
emergence of echinocandin resistance and included Candida isolates with a low and narrow
MIC range. One study considering two clinical trials of micafungin for IC (total 493 cases)
showed a correlation between clinical/mycological response and outcome according to
the AUC/MIC ratio (cut-off 3000) and showed a trend towards improved mycological
response for a micafungin MIC cut-off of <0.5 mg/L (p = 0.07) [62]. The most recent stud-
ies, including a substantial proportion of FKS mutant isolates and limited to C. glabrata
(i.e., the species for which these mutations are more frequent), showed some association
between MIC and outcome [51,52,55,63,64] (Table 3).
Overall, these MIC cut-offs are close to the actual CLSI CBPs, which demonstrated
a good accuracy in identifying FKS mutant isolates [55,65]. Shields et al. showed that
CLSI breakpoints of non-susceptibility for anidulafungin (≥0.25 mg/L) and micafungin
(≥0.12 mg/L) were highly specific for the identification of FKS-mutant C. glabrata isolates
and predicted treatment failure with 23–27% sensitivity and 89–98% specificity [55]. However,
caspofungin CBPs appear as less reliable predictor of FKS mutations, which may be related
to some methodological testing issue and interlaboratory variability of MIC results [16,55].
Whether higher echinocandin doses can overcome resistance in FKS-mutant strains re-
mains a debated question with controversial results in murine models, suggesting that the
effect could be strain-dependent and/or related to the type of mutation [66–68]. It is note-
worthy that such FKS mutations may occur with a consequent fitness cost, which may result
in decreased virulence and lower AUC/MIC ratio for efficacy in murine models [50,66,69].
In addition to the phenomenon of acquired FKS mutations among C. albicans and
C. glabrata, decreased echinocandin susceptibility is observed in C. parapsilosis, which has a
natural mutation at codon A661 of FKS1. However, echinocandin therapy demonstrated
a global response of 60–90% for C. parapsilosis IC in large prospective comparative trials,
which did not differ from that of IC due to other Candida spp. [56–59]. Finally, Fernandez-
Ruiz et al. observed that initial echinocandin treatment had no impact on clinical failure
among 194 cases of C. parapsilosis candidemia of a Spanish cohort [70]. One pharmacody-
namic analysis showed a trend towards improved mycological response of C. parapsilosis
IC to micafungin for an AUC/MIC ratio ≥285, which was about 7-fold lower than for
C. albicans [62]. This might be explained by the fact that C. parapsilosis is considered as a
less-virulent Candida species associated with catheter infection and for which adequate
source control by catheter removal may be sufficient for clearance of the infection.
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Table 3. Clinical studies correlating echinocandin minimal inhibitory concentrations (MIC) and outcome of invasive candidiasis (IC).
Study (First Author, Year, Reference) N Cases Type of IC (Patients) Candida spp. Echinocandin AST Method Outcome Indicator CorrelationMIC/Outcome 1
MIC Cut-Off
for Success
Kartsonis (2005) [60] 114 All IC (~70%non-neutropenic)
C. albicans 38%
NAC 62% CSF NCCLS (M27-A) Clinical response
2 No -
Andes (2011) [62] 493 All IC (~90%non-neutropenic)
C. albicans 44%
NAC 56% MCF CLSI (M27-A) Clinical response
2 Yes AUC/MIC > 3000




AND MIC ≤ 0.12 mg/L
MCF MIC ≤ 0.06 mg/L
CSF MIC ≤ 0.5 mg/L
Alexander (2013) [51] 155 Candidemia (mainlynon-neutropenic) C. glabrata CSF and MCF CLSI (M27-A3) Clinical response
2 (day 10) No -
Farmakiotis (2014) [63] 93 Candidemia (~60%non-neutropenic) C. glabrata All (NS) CLSI (M27-A2) Overall mortality (day 28) Yes CSF MIC ≤ 0.25 mg/L
Beyda (2014) [52] 57 Candidemia (NS) C. glabrata MCF SYO Clinical response 2 (day 14) Yes CSF MIC ≤ 0.12 mg/L
IC: invasive candidiasis, AST: antifungal susceptibility testing, MIC: minimal inhibitory concentration, NAC: non-albicans Candida spp., NCCLS: National Committee for Clinical Laboratory Standards, CLSI:
Clinical and Laboratory Standards Institute (former NCCLS), SYO: Sensititre YeastOneTM, AND: anidulafungin, CSF: caspofungin, MCF: micafungin, NS: not specified. 1 Assessment of correlation MIC/outcome:
Yes (p < 0.05)/Trend (p < 0.2)/No (p ≥ 0.2). 2 Clinical response was usually assessed with composite parameters including clinical response, microbiological cure, overall mortality, relapsing candidemia.
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3.5. Current Issues/Pitfalls for Candida spp. AST
CLSI and EUCAST have now harmonized their CBPs for Candida spp. and azoles
(Table 1). Relative robust data support the C. albicans CBP for fluconazole, while it seems
less evident for NAC, in particular for C. glabrata, for which both CLSI and EUCAST
abstain from a clear categorization and consider most isolates to fall in the susceptible-dose
dependent or intermediate category.
For echinocandins, there is robust evidence of the association of FKS mutations among
C. albicans/glabrata and failure of therapy. CLSI CBPs display acceptable reliability for their
identification. Discrepancies between CLSI and EUCAST CBPs, which can be attributed
to differences in testing methods, remain an important issue (Table 1). Microbiology labo-
ratories should be aware to use the appropriate CBPs according to their testing method,
in particular, regarding the widely used commercial kit Sensititre YeastOneTM, for which
CLSI CBPs are recommended. Use of EUCAST criteria with this method would result
in overestimation of echinocandin resistance. The role of caspofungin AST and its inter-
pretation is still a matter of debate, and both CLSI and EUCAST recommend to rely on
anidulafungin/micafungin MICs for interpretation.
The role and interpretation of AST in NAC other than C. glabrata still remain unclear.
In particular, there is currently no established CBPs for emerging Candida auris, which
exhibit a large variability of MIC values and a remarkable ability to rapidly induce resis-
tance to all three antifungal drug classes [71,72]. These isolates should be tested and results
interpreted using CBPs derived from other Candida spp. [72], but their actual relevance
should be investigated in clinical studies.
3.6. Invasive Aspergillosis (IA)
IA and invasive mold infections in general are challenging for the assessment of CBPs
because of their frequent lack of microbiological documentation and therefore of MIC data.
Over 50% of IA are nowadays diagnosed on the basis of a positive galactomannan only,
without recovery of the mold in culture [73]. Currently, AST is not routinely recommended
for all Aspergillus isolates [4]. However, emerging pan-azole resistance among A. fumigatus
makes that this practice is encouraged for documented IA [4] and raises the need to better
correlate the results of AST testing with response to therapy.
3.7. Amphotericin B
Amphotericin B (AMB) formulations are still widely used for the treatment of IA,
in particular, as initial pre-emptive therapy and/or in the setting of breakthrough to azole
prophylaxis [3,4,74]. With the exception of A. terreus exhibiting innate resistance to AMB,
and to a lesser extent A. flavus, the other common pathogenic Aspergillus spp. includ-
ing A. fumigatus exhibit low and narrow ranges of MICs [75]. Acquired AMB resistance
among A. fumigatus seems to be extremely rare, as it is associated with fitness cost, and its
mechanisms are not well understood [76].
The Cmax/MIC was the best parameter predicting response to therapy in mice with
an optimal ratio at 2.4 [77]. All formulations of AMB induce a dose-dependent response
that can also be linked to the AUC/MIC, but there is very distinct concentration-response
and AUC-response profiles between the three AMB formulations (deoxycholate, liposomal,
and lipid complex) [78,79].
Pk/Pd murine models of IA assessing the efficacy of AMB against Aspergillus spp.
with different MIC levels provided controversial results, some suggesting a MIC/outcome
correlation and others not [80–82].
Clinical studies are also scarce with very limited number of cases, and include a
mixture of Aspergillus spp. (including A. terreus) [83,84] (Table 4). Only one study identi-
fied a cut-off of ≥2 mg/L to predict failure, which may be actually more species-related
(A. terreus/flavus) than MIC-related.
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Table 4. Clinical studies correlating antifungal minimal inhibitory concentrations (MIC) and outcome of invasive aspergillosis (IA).




Heo (2017) [85] 107 Proven/probable
2
(HEM)




L-AmB (54%) CLSI (M38-A2) Overall mortality (day 42) No -
Andes (2019) [86] 22 Proven/probable
2
(mainly HEM) NS VRC
CLSI (M38-A2)
EUCAST
Overall mortality (day 42)
Clinical response No -




A. fumigatus (32 with cyp51A
mutations 3) VRC (79%)
4 EUCAST Overall mortality (day 42and 90) Yes MIC ≤ 2 mg/L
Andes (2019) [86] 49 Proven/probable
2
(mainly HEM) NS ISA
CLSI (M38-A2)
EUCAST
Overall mortality (day 42)
Clinical response No -
Amphotericin B MIC/outcomes
Lass-Flörl (1998) [83] 29 Proven/probable
2
(HEM)
A. flavus (12), A. terreus (9),
A. fumigatus (8) d-AmB NCCLS (M27-P) Overall mortality Yes MIC ≤ 1 mg/L




Others: NS L-AmB NCCLS (M38-A) Clinical response (day 14) No -
MIC: minimal inhibitory concentration, IA: invasive aspergillosis, AF: antifungal, AST: antifungal susceptibility testing, HEM: hematologic cancer patients, VRC: voriconazole, ISA: isavuconazole, d-AmB:
deoxycholate amphotericin B, L-AmB: lipid formulation of amphotericin B, EUCAST: European Committee on Antimicrobial Susceptibility testing, NCCLS: National Committee for Clinical Laboratory Standards,
CLSI: Clinical and Laboratory Standards Institute (former NCCLS), NS: not specified. 1 Assessment of correlation MIC/outcome: Yes (p < 0.05)/Trend (p < 0.2)/No (p ≥ 0.2). 2 IA classification: proven/probable
according to EORTC-MSG criteria (or equivalent) for immunocompromised patients [88], proven/putative according to the AspICU algorithm for intensive care units patients [89]. 3 No mutations known
to be associated with azole resistance (in particular TR34/L98H or TR46/Y121F/T289A). 4 Voriconazole was the first-line AF in 79% of cases. N.B.: Only studies limited to IA are mentioned in this Table.
Pharmacodynamics studies including a mix of different invasive fungal infections [90–94] have not been included in this Table.
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3.8. Azoles
Voriconazole is the first-line treatment of IA, while the novel triazoles isavuconazole
and posaconazole represent alternative therapeutic options [3,4]. A. fumigatus, the most
common cause of IA, and other pathogenic Aspergillus spp. exhibit low and narrow MIC
ranges to these drugs [95–97].
Acquired azole resistance among A. fumigatus is an emerging issue, which is cur-
rently observed at variable incidence around the world, from <1% to 15% (e.g., in the
Netherlands) [98,99]. Isolates harboring the typical TR34/L98H mutation in the cyp51A
gene usually display pan-azole resistance with high MIC values (≥8 µg/mL for voricona-
zole) [98,100]. Other mutations have been described, with variable levels of resistance [101].
One study suggests that the proportion of A. fumigatus cyp51A-mutant isolates becomes
significant (≥10%) among isolates with a MIC ≥2 mg/L for voriconazole and ≥0.5 mg/L
for posaconazole [100]. Acquired azole resistance is much less frequently reported among
the other common pathogenic Aspergillus spp. (A. flavus, A. niger, A. terreus), but could be
an underrecognized issue [102].
In murine Pk-Pd models of IA, the AUC/MIC ratio is the most reliable index for
exposure-response analyses [103–108]. A standard dosing regimen is expected to achieve
appropriate exposure for efficacy against A. fumigatus isolates with a MIC ≤1 or 2 mg/L
for voriconazole, ≤0.25 mg/L for posaconazole and ≤2 mg/L for isavuconazole [103–108].
These values are close to the established epidemiological cut-off values (ECVs) [95–97].
Pk-Pd murine models showed that the efficacy of triazoles was significantly decreased
against cyp51A-mutant isolates, but could be improved with escalating doses [104–108].
Most clinical pharmacodynamic studies of azoles and IA have assessed the correlation
between pharmacologic parameters and outcome, instead of MIC/outcome. Effectively,
MIC documentation is lacking in many IA cases and, before the recent emergence of
azole resistance, most A. fumigatus isolates exhibited a low and narrow range of MICs.
On the contrary, azole drugs (mainly voriconazole and to some degree posaconazole)
display important pharmacokinetic inter- and intra-individual variability. As the trough
concentration (Ctrough) correlates with AUC [109], it can be easily monitored in clinical
practice. These studies showed an association between a voriconazole Ctrough ≥1 to
2 mg/L, or a Ctrough/MIC ratio >2 to 10 and therapeutic success, but are hampered by their
very heterogeneous dataset including all types of IFI (usually a mix of IA and IC) [90–94].
These results are however supported by an in vitro model of IA using cell culture of the
human alveolus and mimicking voriconazole pharmacokinetics in humans suggesting that
a Ctrough/MIC ratio of 1 to 2 is a predictor of success [104].
Studies correlating MIC/outcome and limited to IA are scarce, but are actually needed
with the raising concern of emerging azole resistance. Their results are controversial
(Table 4), which is mainly due to the low proportion of cyp51A mutant isolates (affecting
their actual statistical power) and the confounding factor of non-azole drugs (in partic-
ular, use of amphotericin B among patients infected with azole-resistant isolates, which
represents an important bias in outcome analyses). The most relevant results have been
recently reported in a large Dutch cohort of IA including a high proportion of cyp51A
mutant isolates and in which the majority of patients have received initial voriconazole
therapy [87]. In this study, a voriconazole MIC cut-off >2 mg/L was associated with a
higher mortality rate (47% vs. 24% for MIC ≤2 mg/L, p = 0.02).
The efficacy of increased azole doses for the treatment of cyp51A-mutant isolates is still
an open question. One study reported an overall good response to high-dose posaconazole
(targeted Ctrough > 3 mg/L) in a series of 7 IA with resistant isolates (MIC ≥ 16 mg/L, most
of them with documented cyp51A mutations) [110].
In addition to acquired resistance among A. fumigatus, some rare cryptic Aspergillus spp.
(e.g., A. calidoustus, A. lentulus) intrinsically exhibit decreased susceptibility to azoles [111–113].
Limited data are available regarding the efficacy of azoles against these cryptic Aspergillus spp.
Voriconazole displayed similar efficacy than amphotericin B against Aspergillus calidoustus in
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a Galleria mellonella model of infection and in an retrospective outcome analysis of clinical
cases, while this species usually exhibits high MICs to voriconazole (4–8 mg/L) [112,114].
3.9. Echinocandins
Echinocandins only have fungistatic activity against Aspergillus spp. and are consid-
ered as second-line or third-line therapy of IA in case of intolerance or failure of azoles
or amphotericin B [3,4]. In vitro, the fungistatic effect is observed at relatively low con-
centrations with a very narrow range of minimal effective concentrations (MEC). Variable
ECVs have been reported across studies, which actually reflects variations in methods
and reading interpretation [115–117]. Acquired echinocandin resistance among Aspergillus
spp. can result from mutation in the target gene (FKS1) and seems to be an extremely rare
event as the cost of such mutations may be an important loss of fitness [118,119]. The effect
of echinocandins against A. fumigatus is dose-dependent, but caspofungin may have a
paradoxical effect in vitro (i.e., initial dose-dependent effect followed by loss of activity
at increasing concentrations), which was also observed in murine models [120–122]. In a
murine Pk/Pd model of IA, the caspofungin Cmax/MEC ratio appeared as the most reliable
indicator with optimal efficacy at 10–20 [122].
There are no data correlating echinocandins MICs and IA outcome. Considering the
narrow MIC distribution and the extreme rarity of acquired echinocandin resistance among
A. fumigatus, it is unlikely that such analyses would provide any relevant conclusions.
3.10. Current Issues/Pitfalls for Aspergillus spp. AST
The MIC interpretation and CBP definitions for Aspergillus spp. continue to be a matter
of uncertainty. While EUCAST has defined clinical CBPs for azoles and amphotericin B,
CLSI abstains from a susceptibility/resistance categorization and only provides ECVs
(Table 1). Although there is good agreement between these CBP/ECV values, some issues
should be outlined.
For amphotericin B, the very narrow interval of categorization proposed by EUCAST
(i.e., ≤1 mg/L susceptible, 2 mg/L intermediate and ≥4 mg/L resistant) is concerning.
Effectively, these CBPs fall within the narrow range of MIC distribution of A. fumigatus
(1 to 4 mg/L), and a single-dilution difference could be not significant, considering the
acceptable technical variability of ± two dilutions for AST testing of molds. The concept of
defining CBPs for amphotericin B and A. fumigatus is debated in the absence of established
and clinically-relevant mechanisms of resistance to this drug. MIC differences in this setting
are more likely to reflect technical variability.
For azoles, there is relatively good evidence to suggest that voriconazole therapy is ap-
propriate for isolates with MIC ≤2 mg/L, provided appropriate monitoring of voriconazole
concentrations for a targeted Ctrough ≥2 mg/L. Presence of cyp51A mutation actually repre-
sents the most reliable predictor of failure of azole therapy and these isolates usually exhibit
high MICs (≥8 mg/L), which can be easily identified. Because therapeutic options of azole-
resistant IA are very limited, the potential role of higher azole doses for a dose-dependent
effect should be further investigated. However, the relatively narrow therapeutic range of
azoles, especially voriconazole, represents a limitation to this approach.
For echinocandins, current data do not support a recommendation for AST and MIC
interpretation. The fact that widely used commercial kits (e.g., Sensititre YeastOneTM) in-
clude echinocandin testing in their panel could be confusing for the clinicians, in particular,
because of the low MICs of Aspergillus spp., which actually correspond to MECs and cannot
be translated in good efficacy.
Regarding the testing methods, there is an increased use of more convenient and less
time-consuming approaches, such as E-test. It should be outlined that E-test for Aspergillus
spp. usually provide lower MICs (in particular for posaconazole) compared to those
obtained by standard CLSI or EUCAST microbroth dilution methods [14].
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3.11. Non-Aspergillus Invasive Mold Infections (NAIMIs)
NAIMIs consist mainly of invasive mucormycosis (IM), followed by disseminated fusar-
iosis and scedosporiosis. Fungal pathogens causing these infections share the characteristics
of resistance or decreased susceptibility to at least one or two of the currently available
antifungal drug classes and are considered as “difficult to treat”. Some of them have a highly
predictable antifungal susceptibility profile (e.g., Scedosporium spp.), but others exhibit a wide
range of MIC distribution. This is notably the case for species of the order Mucorales (causal
agents of IM) with respect to the broad-spectrum azoles (posaconazole and isavuconazole)
and for Fusarium spp. (causal agents of fusariosis) and voriconazole [123–125]. To a lesser
extent, variable MICs to amphotericin B are also observed for these mold species [124,125].
Despite these observations, mechanisms of acquired resistance remain largely unknown
among non-Aspergillus molds.
Murine models are scarce and have failed to demonstrate a correlation between MICs
and outcome for IM and fusariosis [126–128]. This lack of association could be partly
explained by the overall poor efficacy of antifungals in these models and/or by the narrow
MIC ranges of the tested strains. For Scedosporium apiospermum infection, one study in mice
suggested a correlation between voriconazole MICs >2 mg/L and failure [129].
Clinical pharmacodynamic studies for NAIMIs are quasi-absent because of the rarity
of the disease and the frequent lack of positive culture results, in particular for IM. One
retrospective small-series of NAIMIs (consisting mainly of mucormycosis) suggested a cor-
relation between amphotericin B MIC >0.5 mg/L and failure of therapy [130]. For fusariosis,
voriconazole, despite its wide MIC distribution and frequent high MIC values (≥8 mg/L),
was found to be equally effective than lipid formulations of amphotericin B (exhibiting
overall lower MICs) [131,132].
Most importantly, the studies reporting factors associated with NAIMI outcomes demon-
strated that non-pharmacologic factors, such as the type and duration of immunosuppression,
the localization and extension of disease, the timing of appropriate antifungal therapy, and
surgical interventions actually represented the best predictors of outcome [132–135].
3.12. Current Issues/Pitfalls for Non-Aspergillus Molds AST
There is no recommendation of AST testing for non-Aspergillus molds as MICs are
considered as unreliable predictors of outcome and actual mechanisms of acquired resis-
tance are unknown. Nonetheless, a wide range of MIC distribution is frequently observed,
in particular for Mucorales and posaconazole/isavuconazole, and for Fusarium spp. and
voriconazole. A better understanding of the causes and actual significance of these MIC
variations is needed.
4. Conclusions and Perspectives
The assessment of CBPs for fungi remains a difficult task, as illustrated by the on-
going processes of revision and harmonization of the CLSI and EUCAST criteria. AST is
recommended for Candida spp. (azoles and echinocandins) and Aspergillus fumigatus (azoles)
isolated in invasive diseases. Notably, the mechanisms of resistance for these antifun-
gals/pathogens are well-described (i.e., acquired mutations) and the performance of CBPs
or ECVs seems acceptable for their identification with a high probability of failure of therapy.
For Candida/echinocandins and Aspergillus/azoles, a single mechanism of resistance (i.e.,
mutations in hotspots of the target gene) seems to be by far the most clinically relevant.
Therefore, genotypic rather than phenotypic characterization of the isolates might be a most
reliable indicator to guide therapeutic choices. Direct identification of these mutations by
PCR tools has also the considerable advantage to provide more rapid results compared to
AST that requires initial positive cultures and subcultures resulting in important delays.
Several PCR kits have been developed for the rapid and accurate identification of FKS
mutations (for Candida spp.) or cyp51A mutations (for Aspergillus spp.) on cultures or
directly on the clinical samples [136–138]. Albeit promising, these molecular diagnostic
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tools might be more costly with limited availability. Therefore, AST is expected to remain
an important pillar for resistance detection.
Because of the heterogeneity of AST methods, the area of technical uncertainty and
the difficulties in MIC interpretation (as mentioned above), input by mycology experts
is required for the interface between the laboratory and beside in order to avoid misin-
terpretation. Indications for AST should also be clearly delineated and each request of
fungal AST falling outside these indications should be carefully evaluated and discussed
with the clinicians. Systematic AST may have an interest for epidemiological purposes
and monitoring of resistance, but can also be confusing for the clinicians in the absence of
expert guidance for interpretation.
The significance of MIC results should always be interpreted in a global context,
taking into account the multiple parameters that can affect outcome, including host fac-
tors, the pathogenesis of the disease, the drug bioavailability, and non-pharmacologic
interventions. Lack of response to therapy despite a susceptible fungal pathogen and an
appropriate therapy remains a relatively frequent situation. On the contrary, a favorable
response despite apparently high MIC of the fungus to the ongoing antifungal drug can
also be observed. Several mechanisms that can influence clinical response (Figure 1) and
that are not reflected by MIC may occur. For instance, acquired mutations of resistance are
often associated with a fitness loss and decreased virulence. Heteroresistance can also occur
with an undetected subpopulation of resistant clones despite apparent low MIC. Such
phenomenon might be observed in patients with sanctuary sites and poor drug penetration
(e.g., intra-abdominal IC, aspergilloma, or large necrotic mass in IA or IM).
Finally, several priority axes of research in this complex topic can be highlighted.
On the molecular laboratory side, there is a need to improve our understanding of the
clinically-relevant mechanisms of acquired resistance, in particular regarding azole resis-
tance other than cyp51A mutations in Aspergillus and the still largely unknown mechanisms
of resistance in non-Aspergillus molds. On the clinical microbiology laboratory side, efforts
should be pursued for more uniform practices and interpretive criteria. On the clinical
side, studies of MCI/outcome correlation should be undertaken in large multicenter co-
horts of relatively homogenous patient populations, allowing for integration of potential
confounding factors in multivariate analyses.
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